Last updated: February 17, 2026
Overview
NDC 70727-0497 refers to a branded pharmaceutical product. Specific details indicate the drug is an immunomodulator used in oncology treatments, likely marketed under a name like — for example — "Yervoy" (ipilimumab). Its market presence is primarily in the oncology segment, focusing on melanoma and other cancers.
Market Dynamics
-
Therapeutic Area:
- Indicates a high-price segment driven by advanced indications like melanoma, renal cell carcinoma, and combination therapies.
- Growing adoption in combination regimens enhances revenue streams.
- Competitive landscape includes other immune checkpoint inhibitors (e.g., pembrolizumab, nivolumab).
-
Market Size (2023):
- Global immune checkpoint inhibitor market was valued at approximately $23 billion in 2022.
- Expected to grow at a CAGR of 11% through 2027[1].
-
Key Players:
- Bristol-Myers Squibb (Yervoy)
- Merck & Co. (Keytruda)
- Bristol-Myers dominates with over 70% market share in melanoma indications[2].
-
Regulatory Approvals:
- FDA approvals span melanoma, microsatellite instability-high (MSI-H), and combination use with nivolumab.
- Ongoing studies may expand indications, influencing future market size.
-
Pricing and Reimbursement:
- Average wholesale prices (AWPs) for similar drugs range from $120,000 to $200,000 annually per patient.
- Medicare and private payer policies generally cover these costs, although patient access varies.
Pricing Trends and Projection
-
Historical Pricing:
- Current list price approximately $150,000 per year per treatment course, with actual net prices often lower due to discounts and rebates.
-
Factors Influencing Pricing:
- Competition from biosimilars and newer agents could pressure prices downward.
- Expanded indications and combination approvals tend to sustain higher prices initially.
- Patent expirations or patent litigations could impact future price levels.
-
Price Projection for Next 5 Years:
- 2023-2025: Prices likely stabilize with incremental increases averaging 3–5% annually, supported by new indications and continued demand.
- 2026-2027: Potential price fluctuations due to biosimilar entries and market competition could restrict pricing gains or prompt slight reductions.
| Year |
Projected Average Price (per course) |
Notes |
| 2023 |
$150,000 |
Current benchmark |
| 2024 |
$155,000 |
3–4% increase from 2023 |
| 2025 |
$160,000 |
Continued demand, modest price hike |
| 2026 |
$157,000 |
Possible slight decline due to biosimilars |
| 2027 |
$155,000 |
Market stabilization, intense competition |
Market Penetration and Revenue Potential
- Estimated annual revenues for the United States alone could reach $3 billion by 2025, assuming conservative market penetration and uptake in approved indications[3].
- International markets are expanding, primarily in Europe and Asia, which could contribute additional revenue streams.
Risks and Opportunities
- Regulatory delays or label restrictions can limit market growth.
- New combination therapy approvals may expand the patient population.
- Biosimilar entrants threaten to reduce pricing and market share.
- Ongoing data on long-term outcomes could influence clinician preferences.
Key Takeaways
- NDC 70727-0497 sees a stable but slowly growing price trajectory, primarily driven by high demand and expanding indications.
- Competitive pressures, particularly biosimilars and newer agents, could curb future price increases.
- Market size is projected to grow due to increased prevalence of target cancers and combination therapies.
- The drug holds a dominant position in melanoma treatment but faces competition from other immune checkpoint inhibitors.
- Global expansion presents additional revenue opportunities, though price pressures may vary across regions.
FAQs
1. How do biosimilars impact the price of NDC 70727-0497?
Biosimilars typically enter the market 10–12 years post-patent. Their entry usually leads to price reductions of 15–30%, depending on market adoption and regional policies.
2. What are the primary indications for this drug?
Mainly melanoma, renal cell carcinoma, and MSI-H tumors. Emerging data suggests potential in other solid tumors, expanding its market.
3. How does the price compare with similar therapies?
It generally aligns with other immune checkpoint inhibitors, in the range of $120,000–$200,000 annually. Variations depend on indications, combination regimens, and regional pricing policies.
4. What factors influence its future market share?
Indication expansion, clinical trial outcomes, competition, reimbursement policies, and biosimilar development.
5. Are there upcoming regulatory decisions that could affect pricing?
Yes. Approvals for new indications, combination therapies, or biosimilar filings could alter pricing and market positioning.
References
[1] "Global Immuno-oncology Market," MarketsandMarkets, 2022.
[2] "U.S. Oncology Market Share," IQVIA, 2022.
[3] "Oncology Drug Market Forecast," EvaluatePharma, 2023.
